Samsung Bioepis Aims To Compete On Higher-Strength Humira In US
FDA Accepts sBLA For 100mg/ml Citrate-Free Version Of Hadlima Biosimilar
Executive Summary
Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.
You may also be interested in...
Sandoz Lines Up Higher-Strength Adalimumab In Europe
Sandoz is looking to enter the European market for high-concentration adalimumab after announcing EMA acceptance of its filing for a 100mg/ml version of its Hyrimoz biosimilar. Celltrion and Stada/Alvotech already have higher-strength rivals to Humira available in Europe.
Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.
Settlement Gives Celltrion Date For US Higher-Strength Humira Biosimilar
Celltrion has secured a US launch date for its higher-strength adalimumab biosimilar, Yuflyma, through a settlement with AbbVie. However, the company will face a number of other Humira rivals in 2023.